Takeda to acquire Maverick Therapeutics

By The Science Advisory Board staff writers

March 9, 2021 -- Takeda Pharmaceutical has exercised its option to purchase T cell-targeted immunotherapy developer Maverick Therapeutics for up to $525 million in upfront and potential milestone payments.

Culminating a collaboration that began in 2017, the acquisition expands Takeda's immuno-oncology portfolio with Maverick's Cobra T-cell engager platform as well as two development candidates for treating solid tumors, according to the vendor. Maverick's lead candidate TAK-186 (formerly known as MVC-101) is a conditionally active T-cell engager that's currently being evaluated in a phase I/II study for the treatment of epidermal growth factor receptor (EGFR)-expressing solid tumors.

In addition, Maverick's AK-280 candidate -- formerly known as MVC-280 -- is expected to enter the clinic in the second half of Takeda's fiscal 2021 for the treatment of patients with B7H3-expressing solid tumors, according to the company. Upon expected closure of the deal in the first quarter of Takeda's fiscal year, Maverick employees, including its team of scientists, will join Takeda's research and development organization.


Copyright © 2021 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here